Sofosbuvir/Velpatasvir
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-SOFOSBUVIR-VELPATASVIR |
|---|---|
| Type | Drug |
| Aliases | EpclusaSOF/VELСофосбувір/Велпатасвір |
| Status | reviewed 2026-04-24 | pending_clinical_signoff |
| Diseases | DIS-HCV-MZL DIS-NODAL-MZL DIS-SPLENIC-MZL |
| Sources | SRC-EASL-HCV-2023 |
Drug Facts
| Class | Pan-genotypic direct-acting antiviral (DAA) — NS5B + NS5A inhibitor |
|---|---|
| Mechanism | Fixed-dose combination: sofosbuvir is an NS5B polymerase inhibitor, velpatasvir is an NS5A replication complex inhibitor. Pan-genotypic activity against HCV genotypes 1-6. |
| Typical dosing | 400/100 mg PO daily × 12 weeks (treatment-naive, no cirrhosis or compensated) |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Warnings
- Risk of HBV reactivation in HCV/HBV coinfected patients
Notes
Primary DAA regimen for pan-genotypic HCV treatment. SVR12 (cure) rate >95% in non-cirrhotic; 85-95% in decompensated cirrhosis (with ribavirin). Cornerstone of antiviral-first strategy for HCV-MZL.
Used By
Regimens
REG-DAA-SOF-VEL- Sofosbuvir/Velpatasvir 12 weeks